NIH Grants & Funding /
Participating Organization: National Cancer Institute (NCI)
| FOA Number | Co-Funders | Title | Clinical Trial | Activity Code | Application Due Date |
|---|---|---|---|---|---|
| PAR-22-084 | National Cancer Institute (NCI) | Epidemiologic Research on Emerging Risk Factors and Liver Cancer Susceptibility (R21 Clinical Trial Not Allowed) | Not allowed | R21 | ClosedJune 16, 2023 | October 16, 2023 | February 16, 2024 | June 16, 2024 | October 16, 2024 | February 16, 2025 |
| PAR-22-083 | National Cancer Institute (NCI) | Epidemiologic Research on Emerging Risk Factors and Liver Cancer Susceptibility (R01 Clinical Trial Not Allowed) | Not allowed | R01 | ClosedJune 05, 2023 | October 05, 2023 | February 05, 2024 | June 05, 2024 | October 05, 2024 | February 05, 2025 |
| RFA-CA-23-033 | National Cancer Institute (NCI) | Implementation Science for Cancer Control in People Living with HIV in Low- and Middle-Income Countries (U01 Clinical Trial Optional) | Optional | U01 | ClosedDecember 16, 2023 |
| RFA-CA-24-005 | National Cancer Institute (NCI) | Cancer Prevention, Detection, Diagnosis, and Treatment Technologies for Global Health (U01 Clinical Trial Optional) | Optional | U01 | ClosedOctober 13, 2023 |
| PAR-21-035 | National Cancer Institute (NCI) | Cancer Prevention and Control Clinical Trials Grant Program (R01 Clinical Trial Required) | Required | R01 | ClosedJanuary 8, 2024 |
| PAR-21-190 | National Cancer Institute (NCI) | Modular R01s in Cancer Control and Population Sciences (R01 Clinical Trial Optional) | Optional | R01 | ClosedNovember 05, 2023 | March 07, 2024 |
| RFA-CA-22-056 | National Cancer Institute (NCI) | Basic/Translational Research on Health Disparities in Underrepresented People Living with HIV (PLWH) and Cancer (R01 Clinical Trial Not Allowed) | Not allowed | R01 | ClosedDecember 16, 2023 |
| RFA-CA-22-057 | National Cancer Institute (NCI) | Basic/Translational Research on Health Disparities in Underrepresented People Living with HIV (PLWH) and Cancer (R21 Clinical Trial Not Allowed) | Not allowed | R21 | ClosedDecember 16, 2023 |
| PAR-22-162 | National Cancer Institute (NCI) | Research Opportunities in Established Cancer Epidemiology Cohort Studies (U01 Clinical Trial Not Allowed) | Not allowed | U01 | Closed July 28, 2023 | February 28, 2024 | July 29, 2024 | February 28, 2025 |
| PAR-21-329 | National Cancer Institute (NCI) | Clinical Characterization of Cancer Therapy-induced Adverse Sequelae and Mechanism-based Interventional Strategies (R01 Clinical Trial Optional) | Optional | R01 | ClosedJune 05, 2023 | October 05, 2023 | February 05, 2024 | June 05, 2024 | October 05, 2024 |
| PAR-22-109 | National Cancer Institute (NCI) | Dissemination and Implementation Research in Health (R21 Clinical Trial Optional) | Optional | R21 | ClosedJune 16, 2023 | October 16, 2023 | February 16, 2024 | June 16, 2024 | October 16, 2024 | February 16, 2025 |
| PAR-22-106 | National Cancer Institute (NCI) | Dissemination and Implementation Research in Health (R03 Clinical Trial Not Allowed) | Not allowed | R03 | ClosedJune 16, 2023 | October 16, 2023 | February 16, 2024 | June 16, 2024 | October 16, 2024 | February 16, 2025 |
| PAR-22-105 | National Cancer Institute (NCI) | Dissemination and Implementation Research in Health (R01 Clinical Trial Optional) | Optional | R01 | ClosedJune 05, 2023 | October 05, 2023 | February 05, 2024 | June 05, 2024 | October 05, 2024 | February 05, 2025 |
| NOT-CA-23-059 | National Cancer Institute (NCI) | Notice of Special Interest (NOSI): Administrative Supplements for the Dog Oncology Grant Supplement (DOGS) Program | Optional | P01, P50, R01, R37, U01, U19, U24, U54 | ClosedJune 16, 2023 |
| PAR-22-216 | National Cancer Institute (NCI) | NCI Clinical and Translational Exploratory/Developmental Studies (R21 Clinical Trial Optional) | Optional | R21 | June 12, 2023 | October 10, 2023 | February 13, 2024 | June 12, 2024 | October 10, 2024 | February 13, 2025 | June 12, 2025 |
| PAR-22-243 | National Cancer Institute (NCI) | Bioengineering Research Grants (BRG) (R01 Clinical Trial Optional) | Optional | R01 | June 05, 2023; October 05, 2023; February 05, 2024; June 05, 2024; October 05, 2024; February 05, 2025; June 05, 2025 |
| RFA-NS-22-034 | Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), National Cancer Institute (NCI), National Center for Advancing Translational Sciences (NCATS), National Center for Complementary and Integrative Health (NCCIH), National Institute of Dental and Craniofacial Research (NIDCR), National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), National Institute of Neurological Disorders and Stroke (NINDS), National Institute on Aging (NIA), National Institute on Alcohol Abuse and Alcoholism (NIAAA) | HEAL Initiative: Discovery and Validation of Novel Targets for Safe and Effective Pain Treatment | Not allowed | R01 | ClosedMarch 02, 2022 to October 02, 2024 |